Prenetics Global Ltd (PRE) stock
Close on Nov 11, 2026Market cap $297.66MP/E –Yield –
Prenetics Global Ltd grew revenue 479.8% to $92.39M over fiscal 2025. Free cash flow was -$22.03M. At the latest close the market valued the company at $297.66M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $297.66M
- P/E ratio
- –
- Price to sales
- 3.22
- Price to book
- 1.90
- Dividend yield
- –
- Free cash flow yield
- -7.40%
Fundamentals
- Revenue
- $92.39M
- Net income
- -$37.71M
- EPS, diluted
- -$2.68
- Free cash flow
- -$22.03M
Trading
- Previous close
- $17.23
- Open
- $17.84
- Day's range
- $17.58 – $18.39
- Volume
- 148,728
- Average volume (20 days)
- 184,273
- Beta (5 years)
- 0.60
- 52-week range
- $11.37 – $27.24
- RSI (14 days)
- 45.1
- Volatility (1 year)
- 81.6%
- Relative volume
- 0.67×
- WACC
- 7.9%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRE | S&P 500 | Difference | PRE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -19.2% | -2.4% | −16.8 pts | ||
| 3 months | -7.2% | -1.2% | −6.1 pts | ||
| Year to date | +12.0% | +12.3% | −0.3 pts | ||
| 1 year | +36.4% | +12.4% | +24.0 pts | ||
| 3 years | +245.9% | +78.8% | +167.1 pts | +51.2% | +21.4% |
| 5 years | -84.6% | +75.2% | −159.8 pts | -31.3% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Prenetics Global filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Prenetics Global
Pharmaceutical Preparations
Prenetics is a consumer health and longevity enterprise that develops science-backed nutritional products and genetic testing solutions. The organization operates through two primary business units: IM8, its core consumer health brand, and CircleDNA, its prevention brand. IM8 provides daily nutritional and cellular health supplements, including all-in-one daily formulations, longevity supplements, and bundled regimens. CircleDNA delivers personalized genetic testing kits using next-generation sequencing across health, wellness, and disease risk categories. The company sells its offerings directly to retail consumers worldwide through proprietary e-commerce platforms and subscription plans.
Company profile, executives and historyPrenetics Global stock: common questions
What is Prenetics Global's stock price?
PRE closed at $17.64 on Nov 11, 2026, up 2.38% on the day. Over the past 52 weeks it traded between $11.37 and $27.24.
What is Prenetics Global's market cap?
Prenetics Global was worth $297.66M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PRE's P/E ratio?
Prenetics Global lost money over fiscal 2025 (diluted EPS -$2.68), so it has no meaningful P/E ratio.
How much revenue does Prenetics Global make?
Prenetics Global reported revenue of $92.39M for fiscal 2025, up 479.8% from a year earlier.
Does Prenetics Global pay a dividend?
No. Prenetics Global has not paid a cash dividend over the last twelve months.
How has PRE stock performed over the past year?
Including dividends, PRE returned +36.4% over the past year, against +12.4% for the S&P 500.
Who are Prenetics Global's competitors?
Companies most similar to Prenetics Global by business, industry and size include LFVN, LAB, ZYBT, MTEX, MRVI.
See a number that looks wrong?